Browsing Institutt for informatikk by Author "Nord, Silje"

Now showing items 1-5 of 5

  • Canine Mammary Tumours Are Affected by Frequent Copy Number Aberrations, including Amplification of MYC and Loss of PTEN 
    Borge, Kaja Sverdrup; Nord, Silje; Van Loo, Peter; Lingjærde, Ole Christian; Gunnes, Gjermund; Alnæs, Grethe I Grenaker; Solvang, Hiroko Kato; Luders, Torben; Kristensen, Vessela N.; Børresen-Dale, Anne-Lise; Lingaas, Frode (Journal article / Tidsskriftartikkel / PublishedVersion; Peer reviewed, 2015)
    Background Copy number aberrations frequently occur during the development of many cancers. Such events affect dosage of involved genes and may cause further genomic instability and progression of cancer. In this survey, ...
  • Integrative clustering reveals a novel split in the luminal A subtype of breast cancer with impact on outcome 
    Aure, Miriam R; Vitelli, Valeria; Jernström, Sandra; Kumar, Surendra; Krohn, Marit; Due, Eldri U; Haukaas, Tonje H; Leivonen, Suvi-Katri; Vollan, Hans K M; Lüders, Torben; Rødland, Einar; Vaske, Charles J; Zhao, Wei; Møller, Elen K; Nord, Silje; Giskeødegård, Guro F; Bathen, Tone F; Caldas, Carlos; Tramm, Trine; Alsner, Jan; Overgaard, Jens; Geisler, Jürgen; Bukholm, Ida R K; Naume, Bjørn; Schlichting, Ellen; Sauer, Torill; Mills, Gordon B; Kåresen, Rolf; Mælandsmo, Gunhild M; Lingjærde, Ole C; Frigessi, Arnoldo; Kristensen, Vessela N; Børresen-Dale, Anne-Lise; Sahlberg, Kristine K (Journal article / Tidsskriftartikkel / PublishedVersion; Peer reviewed, 2017)
    Background Breast cancer is a heterogeneous disease at the clinical and molecular level. In this study we integrate classifications extracted from five different molecular levels in order to identify ...
  • The longitudinal transcriptional response to neoadjuvant chemotherapy with and without bevacizumab in breast cancer 
    Silwal-Pandit, Laxmi; Nord, Silje; Gythfeldt, Hedda; Møller, Elen Kristine; Fleischer, Thomas; Rødland, Einar Andreas; Krohn, Marit; Borgen, Elin; Garred, Øystein; Olsen, Tone; Vu, Phuong Ngoc Thi; Skjerven, Helle; Fangberget, Anne; Holmen, Marit Muri; Schlichting, Ellen; Wille, Elisabeth; Stokke, Mette Norberg; Vollan, Hans Kristian Moen; Kristensen, Vessela N.; Langerød, Anita; Lundgren, Steinar; Wist, Erik; Naume, Bjørn; Lingjærde, Ole Christian; Børresen-Dale, Anne-Lise; Engebråten, Olav (Journal article / Tidsskriftartikkel / AcceptedVersion; Peer reviewed, 2017)
    Purpose: Chemotherapy-induced alterations to gene expression are due to transcriptional reprogramming of tumor cells or subclonal adaptations to treatment. The effect on whole-transcriptome mRNA expression was investigated ...
  • Time series analysis of neoadjuvant chemotherapy and bevacizumab-treated breast carcinomas reveals a systemic shift in genomic aberrations 
    Höglander, Elen K; Nord, Silje; Wedge, David C; Lingjærde, Ole C; Silwal-Pandit, Laxmi; Gythfeldt, Hedda v; Vollan, Hans K M; Fleischer, Thomas; Krohn, Marit; Schlitchting, Ellen; Borgen, Elin; Garred, Øystein; Holmen, Marit M; Wist, Erik; Naume, Bjørn; Van Loo, Peter; Børresen-Dale, Anne-Lise; Engebraaten, Olav; Kristensen, Vessela (Journal article / Tidsskriftartikkel / PublishedVersion; Peer reviewed, 2018)
    Background Chemotherapeutic agents such as anthracyclines and taxanes are commonly used in the neoadjuvant setting. Bevacizumab is an antibody which binds to vascular endothelial growth factor A (VEGFA) ...
  • Time series analysis of neoadjuvant chemotherapy and bevacizumab-treated breast carcinomas reveals a systemic shift in genomic aberrations 
    Høglander, Elen; Nord, Silje; Wedge, David C; Lingjærde, Ole Christian; Silwal-Pandit, Laxmi; Gythfeldt, Hedda; Vollan, Hans Kristian Moen; Fleischer, Thomas; Krohn, Marit; Schlichting, Ellen; Borgen, Elin; Garred, Øystein; Holmen, Marit Muri; Wist, Erik; Naume, Bjørn; Van Loo, Peter; Børresen-Dale, Anne-Lise; Engebråten, Olav; Kristensen, Vessela N. (Journal article / Tidsskriftartikkel / PublishedVersion; Peer reviewed, 2018)
    Background: Chemotherapeutic agents such as anthracyclines and taxanes are commonly used in the neoadjuvant setting. Bevacizumab is an antibody which binds to vascular endothelial growth factor A (VEGFA) and inhibits its ...